ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
8 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
376
|
70K
|
8
|
|
ASX - By Stock
|
EYE |
Re:
The Bear Room
|
|
TheAnalyst007
|
287 |
51K |
4 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
287
|
51K
|
4
|
|
ASX - By Stock
|
ZIP |
Re:
There is NOT going to be a US listing
|
|
TheAnalyst007
|
32 |
6.5K |
7 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
32
|
6.5K
|
7
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Ceasing to be a substantial holder
|
|
TheAnalyst007
|
4 |
1.2K |
0 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
4
|
1.2K
|
0
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
TheAnalyst007
|
14K |
5.3M |
10 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
14K
|
5.3M
|
10
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Ceasing to be a substantial holder
|
|
TheAnalyst007
|
4 |
1.2K |
6 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
4
|
1.2K
|
6
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Chart Thread
|
|
TheAnalyst007
|
342 |
107K |
5 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
342
|
107K
|
5
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Security Class Reinstatement to Quotation- OPTOB
|
|
TheAnalyst007
|
276 |
69K |
2 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
276
|
69K
|
2
|
|
ASX - By Stock
|
BMT |
Re:
Ann: Unaudited FY24 results, strong cashflow & good FY25 outlook
|
|
TheAnalyst007
|
26 |
9.0K |
2 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
26
|
9.0K
|
2
|
|
ASX - By Stock
|
ZIP |
Re:
$3 Party
|
|
TheAnalyst007
|
2.7K |
675K |
4 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
2.7K
|
675K
|
4
|
|
ASX - By Stock
|
GYG |
Re:
Morningstars Analysis of GYG and IPO price
|
|
TheAnalyst007
|
224 |
69K |
0 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
224
|
69K
|
0
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Banter and General Comments
|
|
TheAnalyst007
|
12K |
6.3M |
3 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
12K
|
6.3M
|
3
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
TheAnalyst007
|
14K |
5.3M |
7 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
14K
|
5.3M
|
7
|
|
ASX - By Stock
|
ZIP |
Re:
$3 Party
|
|
TheAnalyst007
|
2.7K |
675K |
8 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
2.7K
|
675K
|
8
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Security Class Reinstatement to Quotation- OPTOB
|
|
TheAnalyst007
|
276 |
69K |
1 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
276
|
69K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Banter and general comments
|
|
TheAnalyst007
|
81 |
35K |
8 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
81
|
35K
|
8
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
9 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
376
|
70K
|
9
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
TheAnalyst007
|
1.5K |
771K |
8 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
1.5K
|
771K
|
8
|
|
ASX - By Stock
|
ZIP |
Re:
$3 Party
|
|
TheAnalyst007
|
2.7K |
675K |
24 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
2.7K
|
675K
|
24
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
8 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
8
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
5 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
5
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Chart Thread
|
|
TheAnalyst007
|
342 |
107K |
9 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
342
|
107K
|
9
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
10 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
10
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
4 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
4
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
1 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TheAnalyst007
|
12K |
5.6M |
33 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
12K
|
5.6M
|
33
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
12 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
12
|
|
ASX - By Stock
|
CUV |
Re:
Australia's Greatest Biotech
|
|
TheAnalyst007
|
20 |
8.0K |
6 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
20
|
8.0K
|
6
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
6 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
6
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
9 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
9
|
|
ASX - By Stock
|
PME |
Re:
Ann: PME Full Year Results
|
|
TheAnalyst007
|
28 |
10K |
7 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
28
|
10K
|
7
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
TheAnalyst007
|
14K |
5.3M |
13 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
14K
|
5.3M
|
13
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
15 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
15
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
6 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
6
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
TheAnalyst007
|
14K |
5.3M |
12 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
14K
|
5.3M
|
12
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
TheAnalyst007
|
14K |
5.3M |
10 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
14K
|
5.3M
|
10
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
TheAnalyst007
|
14K |
5.3M |
12 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
14K
|
5.3M
|
12
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Becoming a substantial holder
|
|
TheAnalyst007
|
5 |
1.7K |
2 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
5
|
1.7K
|
2
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
10 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
376
|
70K
|
10
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
13 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
376
|
70K
|
13
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
12 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
376
|
70K
|
12
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Becoming a substantial holder
|
|
TheAnalyst007
|
5 |
1.7K |
3 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
5
|
1.7K
|
3
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
4 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
376
|
70K
|
4
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Ceasing to be a substantial holder
|
|
TheAnalyst007
|
18 |
6.1K |
4 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
18
|
6.1K
|
4
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
6 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
376
|
70K
|
6
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
TheAnalyst007
|
507 |
115K |
6 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
507
|
115K
|
6
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
2 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
376
|
70K
|
2
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
22 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
376
|
70K
|
22
|
|
ASX - By Stock
|
EYE |
Re:
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
1 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
376
|
70K
|
1
|
|
ASX - By Stock
|
EYE |
EYE Summary (August 2024): Incredibly Undervalued
|
|
TheAnalyst007
|
376 |
70K |
32 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
376
|
70K
|
32
|
|